FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact
Executive Summary
FDA's pilot program to conduct post-market safety reviews of new molecular entities has catalyzed labeling changes for Lilly's Cymbalta, but its impact on patient safety remains uncertain
You may also be interested in...
FDA Makes Post-Market Safety Evaluation Comprehensive For All NMEs, BLAs
All new molecular entities and BLAs approved since Sept. 27, 2007, will be subject to the comprehensive post-market safety evaluation process that FDA pilot-tested during the past two years
FDA Makes Post-Market Safety Evaluation Comprehensive For All NMEs, BLAs
All new molecular entities and BLAs approved since Sept. 27, 2007, will be subject to the comprehensive post-market safety evaluation process that FDA pilot-tested during the past two years
FDA's Post-Market NME Safety Reviews "Useful," But May Not Continue
Evaluations lead to labeling changes but were resource-intensive, according to agency's final report on a pilot program involving five NMEs.